Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Cue Biopharma, Inc. CUE
$4.36
-$0.31 (-7.04%)
На 18:00, 12 мая 2023
+60.55%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
204664668.00000000
-
week52high
5.12
-
week52low
2.18
-
Revenue
1245227
-
P/E TTM
-3
-
Beta
2.00380600
-
EPS
-1.55000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 20:30
Описание компании
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Oppenheimer | Outperform | Outperform | 24 авг 2022 г. |
| Oppenheimer | Outperform | Outperform | 21 мар 2022 г. |
| Craig-Hallum | Buy | Buy | 18 мар 2022 г. |
| Berenberg | Buy | 24 ноя 2020 г. | |
| Stifel | Buy | Buy | 20 мая 2020 г. |
| Piper Sandler | Overweight | 21 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Levisetti Matteo | A | 110000 | 110000 | 17 янв 2023 г. |
| DRISCOLL FREDERICK W | A | 10000 | 10000 | 03 янв 2023 г. |
| Fletcher Aaron G.L. | A | 10000 | 10000 | 03 янв 2023 г. |
| HOWSON TAMAR D | A | 10000 | 10000 | 03 янв 2023 г. |
| Kiener Peter A | A | 10000 | 10000 | 03 янв 2023 г. |
| Morich Frank | A | 10000 | 10000 | 03 янв 2023 г. |
| Millar Kerri-Ann | D | 14311 | 2828 | 22 авг 2022 г. |
| Millar Kerri-Ann | D | 0 | 6667 | 21 авг 2022 г. |
| Millar Kerri-Ann | A | 17139 | 6667 | 21 авг 2022 г. |
| Gray Cameron | D | 0 | 61111 | 14 июн 2022 г. |
Новостная лента
Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference
GlobeNewsWire
08 мая 2023 г. в 08:00
BOSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held at the New York Hilton Midtown, May 15-16, 2023.
7 High-Potential Penny Stocks in the Biotech Sector
InvestorPlace
04 мая 2023 г. в 13:56
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Look at Axsome Therapeutics (NASDAQ: AXSM ), for example.
Cue Biopharma, Inc. (CUE) Q4 2022 Earnings Call Transcript
Seeking Alpha
21 мар 2023 г. в 23:00
Cue Biopharma, Inc. (NASDAQ:CUE ) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Dan Passeri - CEO Matteo Levisetti - Chief Medical Officer Ken Pienta - Clinical Advisory Anish Suri - President and Chief Scientific Officer Kerri Millar - CFO Sara Pai - Surgical Oncologist and Director, Translational Head and Neck Cancer Research, Mass General Hospital Conference Call Participants Ted Tenthoff - Piper Sandler Ren Benjamin - JMP Securities Mark Breidenbach - Oppenheimer Stephen Willey - Stifel Operator Greetings, and welcome to the Cue Biopharma Fourth Quarter and Full Year 2022 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.
Cue Biopharma to Host Business Update Call and Webcast
GlobeNewsWire
15 мар 2023 г. в 08:00
BOSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today that it will host a conference call and webcast to provide a business and clinical update on Tuesday, March 21, 2023 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company's website.
Cue Biopharma to Present at Two February 2023 Scientific Conferences
GlobeNewsWire
01 февр 2023 г. в 08:00
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today that its President and Chief Scientific Officer, Anish Suri, Ph.D., will participate in two scientific conferences this February, the Immuno-Oncology 360 o Summit, taking place February 7-10 in New York, NY, and the Federation of American Societies for Experimental Biology (FASEB) Catalyst Conference, taking place virtually February 8-9, 2023.